The promise and challenges of combination therapies with antibody-drug conjugates in solid tumors

被引：38

作者：

Wei, Qing ^{[1
,2
,3
]}

Li, Peijing ^{[2
,4
]}

Yang, Teng ^{[2
,5
]}

Zhu, Jiayu ^{[6
]}

Sun, Lu ^{[2
,7
]}

Zhang, Ziwen ^{[1
,2
]}

Wang, Lu ^{[8
]}

Tian, Xuefei ^{[2
,9
,10
]}

Chen, Jiahui ^{[2
,3
,11
]}

Hu, Can ^{[2
,3
,11
]}

Xue, Junli ^{[12
]}

Ma, Letao ^{[2
,5
]}

Shimura, Takaya ^{[13
]}

Fang, Jianmin ^{[14
]}

Ying, Jieer ^{[1
,2
,3
]}

Guo, Peng ^{[2
,3
]}

Cheng, Xiangdong ^{[2
,3
,11
]}

机构：

[1] Zhejiang Canc Hosp, Dept Med Oncol, Hangzhou, Zhejiang, Peoples R China

[2] Chinese Acad Sci, Hangzhou Inst Med HIM, Hangzhou, Peoples R China

[3] Upper Gastrointestinal Canc Zhejiang Prov, Key Lab Prevent Diag & Therapy, Hangzhou, Peoples R China

[4] Zhejiang Canc Hosp, Dept Radiat Oncol, Key Lab Head & Neck Canc Translat Res Zhejiang Pro, Hangzhou, Zhejiang, Peoples R China

[5] Zhejiang Univ Technol, Coll Pharmaceut Sci, Hangzhou, Peoples R China

[6] Zhejiang Chinese Med Univ, Hangzhou, Peoples R China

[7] Zhejiang Canc Hosp, Dept Gynecol Oncol, Hangzhou, Peoples R China

[8] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Radiat Oncol, Hangzhou, Zhejiang, Peoples R China

[9] Chinese Acad Sci, Shanghai Inst Mat Med, Shanghai, Peoples R China

[10] Univ Chinese Acad Sci, Hangzhou Inst Adv Study, Coll Mol Med, Hangzhou, Peoples R China

[11] Zhejiang Canc Hosp, Dept Gastr Surg, Hangzhou, Peoples R China

[12] Tongji Univ, Shanghai East Hosp, Sch Med, Dept Oncol, Shanghai, Peoples R China

[13] Nagoya City Univ, Grad Sch Med Sci, Dept Gastroenterol & Metab, Nagoya, Japan

[14] Tongji Univ, Sch Life Sci & Technol, Shanghai, Peoples R China

来源：

JOURNAL OF HEMATOLOGY & ONCOLOGY | 2024年 / 17卷 / 01期

基金：

中国国家自然科学基金;

关键词：

Antibody-drug conjugate; Solid tumor; Combination therapy; Immunotherapy; Targeted therapy; TRASTUZUMAB EMTANSINE T-DM1; METASTATIC BREAST-CANCER; PLUS PEMBROLIZUMAB PEMBRO; DNA-DAMAGE RESPONSE; DERUXTECAN T-DXD; MIRVETUXIMAB SORAVTANSINE; PATIENTS PTS; SACITUZUMAB GOVITECAN; PLATINUM CHEMOTHERAPY; INELIGIBLE PATIENTS;

D O I：

10.1186/s13045-023-01509-2

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Antibody-drug conjugates (ADCs) represent an important class of cancer therapies that have revolutionized the treatment paradigm of solid tumors. To date, many ongoing studies of ADC combinations with a variety of anticancer drugs, encompassing chemotherapy, molecularly targeted agents, and immunotherapy, are being rigorously conducted in both preclinical studies and clinical trial settings. Nevertheless, combination therapy does not always guarantee a synergistic or additive effect and may entail overlapping toxicity risks. Therefore, understanding the current status and underlying mechanisms of ADC combination therapy is urgently required. This comprehensive review analyzes existing evidence concerning the additive or synergistic effect of ADCs with other classes of oncology medicines. Here, we discuss the biological mechanisms of different ADC combination therapy strategies, provide prominent examples, and assess their benefits and challenges. Finally, we discuss future opportunities for ADC combination therapy in clinical practice.

引用

页数：32

共 50 条

[21] Antibody-Drug Conjugates
Peng, Li
Chen, Xiaoyuan
BIOCONJUGATE CHEMISTRY, 2015, 26 (11) : 2169 - 2169
[22] Antibody-drug conjugates
Zolot, Rachel S.
Basu, Satarupa
Million, Ryan P.
NATURE REVIEWS DRUG DISCOVERY, 2013, 12 (04) : 259 - 260
[23] Antibody-drug conjugates
Ornes, Stephen
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2013, 110 (34) : 13695 - 13695
[24] Antibody-drug conjugates in oncology: insights into Current challenges
Al Meslamani, Ahmad Z.
Bostanudin, Mohammad F.
EXPERT OPINION ON BIOLOGICAL THERAPY, 2023, 23 (11) : 1035 - 1038
[25] Antibody-Drug Conjugates
Kulkarni, Ashutosh A.
Gukasyan, Hovhannes J.
PHARMACEUTICAL RESEARCH, 2015, 32 (11) : 3451 - 3452
[26] ANTIBODY-DRUG CONJUGATES
EMBLETON, MJ
BRITISH JOURNAL OF CANCER, 1985, 52 (04) : 653 - 653
[27] Challenges and advances in the assessment of the disposition of antibody-drug conjugates
Kamath, Amrita V.
Iyer, Suhasini
BIOPHARMACEUTICS & DRUG DISPOSITION, 2016, 37 (02) : 66 - 74
[28] Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives
Nicolo, Eleonora
Giugliano, Federica
Ascione, Liliana
Tarantino, Paolo
Corti, Chiara
Tolaney, Sara M.
Cristofanilli, Massimo
Curigliano, Giuseppe
CANCER TREATMENT REVIEWS, 2022, 106
[29] Global research progress in antibody-drug conjugates for solid tumors: Bibliometrics and visualized analysis
Fang, Wenjun
Ma, Xueqing
Liu, Ben
HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2025, 21 (01)
[30] A Systems Pharmacology Model for Drug Delivery to Solid Tumors by Antibody-Drug Conjugates: Implications for Bystander Effects
Jackson K. Burton
Dean Bottino
Timothy W. Secomb
The AAPS Journal, 22

← 1 2 3 4 5 →